Key clinical point: Sentinel lymph node biopsy (SLNB) is not warranted in women with older patients with ductal carcinoma in situ (DCIS) amenable to breast conservation.
Major finding: With a median follow-up of 5.8 years, there were no significant differences in rates of recurrence, ipsilateral breast cancer, or breast cancer-specific mortality for SLNB versus no SLNB.
Study details: Retrospective study including 12,776 women aged 67-94 years who received a diagnosis of DCIS between 2001 and 2013 and underwent breast-conserving surgery.
Disclosures: The research was funded by an award from the Patient-Centered Outcomes Research Institute (PCORI). Dr. Wang reported no disclosures, while co-authors provided disclosures related to Genentech, Eisai, Pfizer, Jonhson & Johnson, and 21st Century Oncology.
Hung P et al. JNCI Cancer Spectr. 2019 Aug 7;3(4):pkz052. doi. 10.1093/jncics/pkz052. https://academic.oup.com/jncics/article/3/4/pkz052/5544720